Study to the humoral and cellular immuneresponse after influenzavaccination in patients with metastasized RCC or GIST treated with a tyrosine kinase inhibitor(sunitinib or sorafenib)

• Conditions: GIST; kidney cancer; 10038363

• Registration Number: NL-OMON32710
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 75

Inclusion Criteria

- Patients with metastasized renal cell carcinoma or GIST who have been treated with sunitinib or sorafenib for at least 4 weeks, or patients with metastasized RCC who did not receive a systemic treatment for their RCC (nephrectomy is allowed)
- Patients who are indicated for influenza vaccination and and have been summoned for this vaccination by their GP
- age >=18 years
- signed Informed Consent Form
-

Exclusion Criteria

- patients with an identified immunodeficiency disorder
- patients that have been treated with corticosteroids in the past 2 weeks or who are still using these (except for a short period <10 days)
- patients that are treated with immunotherapy in the last year (ex. interferon-alpha of IL-2) or who have received another form of targeted therapy (ex. bevacizumab).
- patients with symptoms of influenza at the time of vaccination
- patient with an allergy for

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>cellular and humoral immune response</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>times the influenzavirus occurs</p><br>